FEATURE
Blood Pressure Targets in Diabetes: Insights from the BPROAD Trial
Time to read: 02:31. The study aimed to determine whether an intensive systolic blood pressure target of less than 120 mm Hg is more effective than the standard target of less than 140 mm Hg in reducing major cardiovascular events among patients with type 2 diabetes.
Source: NEJM
Feature
Text
Intensive LDL Cholesterol Lowering in ASCVD: Alternative Strategies and Outcomes
Time to read: 03:23. The aim of this study was to compare To compare the long-term efficacy and safety of an alternative LDL cholesterol–lowering strategy versus a high-intensity statin strategy in patients with ASCVD.
Source: JAMA Cardiology
Text
Testing a New Approach to Hypertension Treatment in Africa
Time to read: 03:53. The trial aimed to determine whether starting treatment with two antihypertensive drugs was at least as effective as standard monotherapy with dose escalation
Source: JAMA
Text
Deprescribing of Antihypertensive Medications and Cognitive Function in Nursing Home Residents
Time to read: 01:30 minutes. Deprescribing antihypertensive medications is linked to a reduced risk of cognitive decline in older adults, particularly those with dementia, highlighting the importance of patient-centred strategies to help preserve cognitive function and minimize potential harm.
Source: JAMA Internal Medicine
Text
Assessing the efficacy of long-term Beta-Blocker treatment interruption versus continuation following Myocardial Infarction
Time to read: 02:08. This recent multicenter, open-label, randomized noninferiority trial sought to evaluate the effects of interrupting long-term beta-blocker treatment in patients with a history of uncomplicated myocardial infarction.
Source: NEJM
Text
Low-Dose Triple-Pill Shows Promise Over Standard Care for Hypertension Treatment
Time to read:1:38. A low-dose triple-pill protocol was more effective in lowering and controlling blood pressure compared to the standard-care protocol, without compromising safety, among Black African adults with uncontrolled hypertension.
Source: JAMA
Text
Study shows no significant reduction in second stroke risk in patients treated with anticoagulant edoxaban
Time to read: 01:50 .A sub analysis of the NOAH-AFNET 6 trial has shown that patients who were treated with the oral anticoagulation edoxaban showed no significant reduction in the risk of a second stroke
Source: European Heart Journal
Text
Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation
Time to read: 00:58. The researchers of this study investigated the prospective associations between the incidence of atrial fibritaliong and blood or adipose tissue levels of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and eicosapentaenoic acid (EPA).
Source: Journal of the American College of Cardiology
Text
